Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Catheter Precision (NYSE:VTAK) announced on Dec 18, 2025 the first purchase order and a multi‑year commitment for its LockeT device at Mater Private Hospital in Dublin, Ireland. Mater Private is described as Ireland's largest electrophysiology center, performing over 1,000 EP procedures annually. The company said LockeT was rapidly adopted during onboarding, with 52 staff trained in two days, and that a European key opinion leader helped introduce the device. The agreement represents an initial commercial expansion into an eighth European country following CE mark receipt and supports the company's international adoption strategy.
Catheter Precision (NYSE American: VTAK) announced that its VIVO system secured a significant multi-year tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary, marking the company’s first installation in Hungary and a push into Central and Eastern Europe. The award was won in partnership with local distributor Fototronic. Installation is anticipated in Q1 2026. The release positions the VIVO system — a non-invasive 3D ventricular tachycardia localization tool used before ablation — as gaining wider adoption following recent multi-year agreements in France, supporting the company’s European expansion strategy.
Catheter Precision (NYSE/American: VTAK) announced the commercial launch of its LockeT suture retention device in Switzerland on December 1, 2025. The first clinical cases were performed at Spitalzentrum Biel under PD Dr. Rainer Zbinden with reported excellent procedural outcomes and positive staff feedback.
The launch follows a strategic distribution agreement with FuMedica AG, enabling rollout to hospitals and clinics across Switzerland and expanding Catheter Precision’s European footprint. The company noted over 10,000 LockeT units shipped globally and highlighted benefits including reduced groin management costs and support for same-day discharge.
Catheter Precision (NYSE:VTAK) said the Centers for Medicare and Medicaid services will add electrophysiology ablation codes to the ASC-Covered Procedures List effective January 1, 2026, a policy change that expands Medicare beneficiary access to EP services in ambulatory surgery centers.
The company framed the change as a new commercialization opportunity for its LockeT suture retention device, saying ASCs seek cost‑effective, workflow‑improving products that enable same‑day discharge and quick hemostasis. The announcement highlights potential for additional patient scheduling and new ASC facilities to adopt LockeT.
Catheter Precision (NYSE:VTAK) announced rapid commercial uptake of its LockeT closure device in South Africa on Nov 20, 2025. With distributor HLC Medical and Dr. Heather Henry-Lines, LockeT was implemented in five hospitals within two months; three hospitals use LockeT daily and two use it routinely. Two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders through the distributor. Management highlighted LockeT as cost effective, workflow-improving, and supportive of rapid hemostasis enabling same-day discharge.
Alaska Airlines (NYSE: ALK) announced a planned 13,000 sq ft Alaska Lounge at San Diego International Airport, described as one of the largest carrier lounges at SAN. Construction is slated to begin in early 2027. The lounge will feature Signature Loungers, private work areas, locally inspired refreshments, a full bar and barista station, and will serve guests traveling to at least 45 nonstop destinations on Alaska and Hawaiian Airlines.
The announcement highlights hub growth, partnership access through Lounge+ and oneworld connections, and local community investments in San Diego.
Catheter Precision (NYSE American: VTAK) reported Q3 2025 revenue of $226,000, up 135% vs Q3 2024, and nine-month revenue of $581,000, up 114% vs YTD 2024.
GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction from Q3 2024; nine-month GAAP net loss was $11,405,000 vs $11,015,000 year‑earlier. Non‑cash charges were $4,232,000 for the nine months.
Commercially, the company cited a Q2 CE Mark for LockeT, growing international interest (Germany, France, Italy, Spain, Portugal, UK, South Africa), five South Africa reorders in October, and the first VIVO purchase order from France. Management said two VIVO clinical studies completed in 2025 delivered clinical evidence supporting VIVO's clinical potential.
Catheter Precision (NYSE/American: VTAK) announced a distribution agreement with FuMedica AG to introduce the LockeT suture retention device to hospitals and clinics across Switzerland, effective October 16, 2025. LockeT is described as a tool to simplify and secure closure of vascular access sites after cardiac procedures, aimed at electrophysiology labs and interventional suites. FuMedica AG will leverage its Swiss clinical relationships and support capabilities to promote LockeT as part of Catheter Precision’s European expansion.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, has received approval for two new patents from the United States Patent and Trademark Office (USPTO).
The first patent, "Methods of Ventricular Arrhythmia Localization Using a 3D Model," will be assigned to Kardionav, a joint venture between Catheter Precision and physicians. The second patent, "Neurostimulation Devices and Methods," focused on improving cardiac ventricular function in heart failure patients, will be assigned to Cardionomix, a majority-owned subsidiary of Catheter Precision.
Catheter Precision (NYSE:VTAK) has secured its first purchase order from Croatia's Dubrava University Hospital following a successful competitive tender bid. The hospital, which treats over 25,000 inpatients and provides healthcare services to more than 400,000 outpatients annually, completed an evaluation of VTAK's VIVO cardiac mapping technology.
Dr. Ivan Zeljkovic, Head of Electrophysiology Lab at Dubrava, praised VIVO's workflow simplicity, mapping accuracy, and potential to enhance procedural efficacy in targeting ventricular arrhythmia locations. This development marks a significant expansion into the European healthcare market for Catheter Precision's cardiac electrophysiology technology.